Abstract
In the past five years, four new oral anticoagulants (NOACs) - dabigatran, rivaroxaban, apixaban and edoxaban - became available for prevention of stroke and systemic embolism among atrial fibrillation (AF) patients. This study compares the health and economic outcomes for AF patients treated with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
